Home » Intercell Signs Vaccine Deal With GlaxoSmithKline

Intercell Signs Vaccine Deal With GlaxoSmithKline

December 11, 2009

Austria’s Intercell said that it has signed a strategic alliance with GlaxoSmithKline to accelerate the development and commercialization of needle-free, patch-based vaccines.
Fox Business

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Intercell Signs Vaccine Deal With GlaxoSmithKline

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

Amgen to Buy Five Prime Therapeutics for $1.9 Billion

Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements